Sanofi and Regeneron Pharmaceuticals, Inc. were late to market with their PD-1 inhibitor Libtayo (cemiplimab-rwlc), but they have won a coveted approval from the US Food and Drug Administration for the first-line treatment of advanced non-small cell lung cancer (NSCLC) as a monotherapy, joining only Merck & Co., Inc.'s Keytruda (pembrolizumab) and Roche Holding AG's Tecentriq (atezolizumab) with that specific indication.
The commercial opportunity is considered a significant one in the field of cancer, but Merck's Keytruda has emerged as the...






